These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7862898)

  • 1. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.
    Möller HJ; van Praag HM; Aufdembrinke B; Bailey P; Barnes TR; Beck J; Bentsen H; Eich FX; Farrow L; Fleischhacker WW
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):221-8. PubMed ID: 7862898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD; Sanger TM; Lu Y; Thieme ME
    Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clozapine and treatment of negative symptoms].
    Lançon C; Farisse J; Llorca PM
    Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
    Langlois-Thery S; Dollfus S; Lesieur P; Petit M
    Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone: how good is the evidence for efficacy?
    Mattes JA
    Schizophr Bull; 1997; 23(1):155-61. PubMed ID: 9050121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
    Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients].
    Nkam I; Langlois-Thery S; Dollfus S; Petit M
    Encephale; 1997; 23(4):267-72. PubMed ID: 9417392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining and measuring negative symptoms of schizophrenia in clinical trials.
    Marder SR; Kirkpatrick B
    Eur Neuropsychopharmacol; 2014 May; 24(5):737-43. PubMed ID: 24275698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs.
    Mauri MC; Moliterno D; Rossattini M; Colasanti A
    Schizophr Res; 2008 Feb; 99(1-3):7-12. PubMed ID: 18055177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset.
    Dunayevich E; Chen CY; Marder SR; Rabinowitz J
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1615-21. PubMed ID: 25172269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
    Wetzel H; Hillert A; Gründer G; Benkert O
    Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depression in first-episode schizophrenia.
    Koreen AR; Siris SG; Chakos M; Alvir J; Mayerhoff D; Lieberman J
    Am J Psychiatry; 1993 Nov; 150(11):1643-8. PubMed ID: 8105706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine.
    Bodkin JA; Cohen BM; Salomon MS; Cannon SE; Zornberg GL; Cole JO
    J Nerv Ment Dis; 1996 May; 184(5):295-301. PubMed ID: 8627275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia.
    Miller DD; Flaum M; Arndt S; Fleming F; Andreasen NC
    Neuropsychopharmacology; 1994 Aug; 11(1):11-20. PubMed ID: 7945739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.